|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,605.00 GBX | +0.31% |
|
-5.83% | -8.80% |
| 03:35am | Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy | MT |
| 02:11am | Keymed Biosciences Expects Return to Profit in H1 | MT |
| Market Cap | 263B 230B 212B 195B 369B 25,295B 376B 2,531B 993B 12,364B 987B 966B 42,614B | P/E 2026 * |
21.2x | P/E 2027 * | 18.6x |
|---|---|---|---|---|---|
| Enterprise Value | 282B 247B 228B 209B 396B 27,142B 403B 2,716B 1,066B 13,266B 1,059B 1,036B 45,725B | EV / Sales 2026 * |
4.46x | EV / Sales 2027 * | 4.11x |
| Free-Float |
96.63% | Yield 2026 * |
1.97% | Yield 2027 * | 2.08% |
Last Transcript: AstraZeneca PLC
| 1 day | -0.21% | ||
| 1 week | -6.17% | ||
| Current month | -11.13% | ||
| 1 month | -5.68% | ||
| 3 months | -15.69% | ||
| 6 months | -10.83% | ||
| Current year | -9.14% |
| 1 week | 9,892 |  | 13,414 |
| 1 month | 9,892 | | 15,126 |
| Current year | 9,892 | | 15,732 |
| 1 year | 9,892 | | 15,732 |
| 3 years | 9,461 | | 15,732 |
| 5 years | 8,029 | | 15,732 |
| 10 years | 3,996 | | 15,732 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 66 | 2012-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 52 | 2021-07-31 |
Jeffrey Pott
CMP | Compliance Officer | - | 2022-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 1999-04-05 | |
Pascal Soriot
BRD | Director/Board Member | 66 | 2012-09-30 |
Philip Broadley
BRD | Director/Board Member | 65 | 2017-04-26 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| Jul. 05 | Free | See Remarks | 2 | 0.0000% | ||
| Jun. 07 | Free | See Remarks | 1 | 0.0000% | ||
| May. 19 | Sell | See Remarks | -11,893 | 0.0008% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.23% | -6.17% | +20.07% | +22.84% | 263B | |
| +1.84% | -3.54% | +48.63% | +162.53% | 1,031B | |
| +1.67% | -2.86% | +52.74% | +58.22% | 595B | |
| +2.81% | -0.12% | +30.98% | +85.13% | 431B | |
| -0.36% | -1.70% | +28.73% | +22.97% | 326B | |
| +0.63% | -1.13% | +29.21% | +44.72% | 277B | |
| +1.84% | +5.19% | -22.34% | -37.17% | 224B | |
| +2.10% | +0.71% | +22.47% | +60.73% | 193B | |
| +1.49% | -1.31% | +21.14% | +71.75% | 164B | |
| +1.87% | +3.98% | +2.46% | -29.68% | 141B | |
| Average | +1.30% | -3.09% | +23.41% | +46.20% | 364.58B | |
| Weighted average by Cap. | +1.44% | -4.02% | +33.13% | +75.65% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 63.22B 55.27B 50.99B 46.87B 88.81B 6,083B 90.32B 609B 239B 2,973B 237B 232B 10,248B | 66.81B 58.41B 53.88B 49.53B 93.85B 6,428B 95.45B 643B 252B 3,142B 251B 245B 10,830B |
| Net income | 12.43B 10.87B 10.03B 9.22B 17.46B 1,196B 17.76B 120B 46.97B 585B 46.69B 45.66B 2,015B | 13.94B 12.18B 11.24B 10.33B 19.58B 1,341B 19.91B 134B 52.65B 655B 52.34B 51.19B 2,259B |
| Net Debt | 19.2B 16.78B 15.48B 14.23B 26.96B 1,847B 27.43B 185B 72.52B 903B 72.09B 70.51B 3,112B | 11.9B 10.41B 9.6B 8.82B 16.72B 1,145B 17.01B 115B 44.97B 560B 44.7B 43.72B 1,929B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-16 | GBX 12,576.00 | +0.08% | 603,070 |
| 26-07-15 | GBX 12,566.00 | +1.63% | 3,346,169 |
| 26-07-14 | GBX 12,364.00 | -1.95% | 3,313,274 |
| 26-07-13 | GBX 12,610.00 | -1.75% | 2,741,916 |
| 26-07-10 | GBX 12,834.00 | -3.89% | 3,355,019 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AZN Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
